- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Subfoveal choroidal neovascularisation
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Brolucizumab – March 2020
Brolucizumab: Solution for intravitreal injection 19.8 mg in 0.165 ml pre-filled syringe; Beovu®
Last updated
3 July 2020